Log In Sign up
The largest database of trusted experimental protocols
> Chemicals & Drugs > Organic Chemical > Risperidone

Risperidone

Risperidone is a atypical antipsychotic medication used to treat schizophrenia, bipolar disorder, and other mental health conditions.
It works by blocking certain receptors in the brain to help reduce symptoms like hallucinations, delusions, and mood swings.
Risperidone is generally well-tolerated, but may cause side effects like weight gain, drowsiness, and extrapyramidal symptoms.
Researchers studying Risperidone can use PubCompare.ai to optimiize their research protocols, identify the best products, and enhance reproducibility and accuaracy in their studies.

Most cited protocols related to «Risperidone»

1
Antipsychotic Dose Equivalency Calculations
Cited 254 times

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2009
Antipsychotic Agents Chlorpromazine Contraceptives, Oral Haloperidol Pharmaceutical Preparations Risperidone
2
Docking Risperidone to DRD2 Homology Models
Cited 28 times
Risperidone was docked to the orthosteric binding site of the DRD2 homology models based on the DRD3 or DRD4 crystal structures, using DOCK3.744 (link). DOCK3.7 places pre-generated flexible ligands into the binding site by superimposing atoms of each molecule on matching spheres, representing favorable positions for individual ligand atoms. Forty-five matching spheres were used here, based on the pose of the corresponding x-ray ligand (eticlopride/nemonapride) in the template structure. The resulting docked ligand poses were scored by summing the receptor-ligand electrostatics and van der Waals interaction energies, and corrected for context-dependent ligand desolvation. Receptor structures were protonated using Reduce48 (link). Partial charges from the united-atom AMBER47 force field were used for all receptor atoms. Grids which evaluate the different energy terms of the DOCK scoring function were precalculated using AMBER47 for the van der Waals term, QNIFFT49 (link),50 (an adaptation of DELPHI) for electrostatics, and ligand desolvation51 (link). Ligands were protonated with Marvin (version 15.11.23.0, ChemAxon, 2015; http://www.chemaxon.com), at pH 7.4. Each protomer was rendered into 3D using Corina52 (Molecular Networks GmbH) and conformationally sampled using Omega53 (link) (OpenEye Scientific Software). Ligand charges and initial solvation energies were calculated using AMSOL54 ,55 .
Wang S., Che T., Levit A., Shoichet B.K., Wacker D, & Roth B.L. (2018). STRUCTURE OF THE D2 DOPAMINE RECEPTOR BOUND TO THE ATYPICAL ANTIPSYCHOTIC DRUG RISPERIDONE. Nature, 555(7695), 269-273.
Publication 2018
Acclimatization Binding Sites DRD2 protein, human DRD4 protein, human Electrostatics eticlopride Ligands nemonapride Protomers Risperidone Roentgen Rays Rumex
3
Longitudinal Bipolar Disorder Phenotyping
Cited 22 times

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2009
Affective Symptoms Antidepressive Agents Antipsychotic Agents Aripiprazole Attention Auditory Perception Barakat syndrome Biopharmaceuticals Bipolar Disorder BLOOD Bupropion Central Nervous System Stimulants Clonazepam Cognition Depression, Bipolar Diagnosis Divalproex Sodium Emotions Face factor A Factor VIII Fingers Genes, vif Hospitalization Inpatient Lamotrigine Lithium Mania Manic Episode Memory Mood Neuropsychological Tests Pharmaceutical Preparations Phenotype Psychological Inhibition Psychotic Disorders Quetiapine Risperidone Schizoaffective Disorder Sedatives Stroop Test Tests, Diagnostic Thyroid Gland Thyroxine Tranquilizing Agents VP-P protocol
4
Pharmacological Preparation and Administration
Cited 14 times
Clozapine was provided as a generous gift to J.H.P. from Novartis (Hanover, NJ, USA). Olanzapine was provided as a generous gift to J.H.P. from Eli Lilly (Indianapolis, IN, USA). Clozapine, olanzapine, and risperidone were supplied to D.W. by the National Institute of Mental Health’s Chemical Synthesis and Drug Supply Program. Haloperidol, prazosin, propranolol, and ritanserin were purchased from Sigma-Aldrich (St. Louis, MO, USA). J.H.P. and M.S.F. obtained CNO from the Rapid Access to Investigative Drug Program funded by the National Institute of Neurological Disorders and Stroke. D.W. obtained CNO from the National Institute on Drug Abuse Drug Supply Program.
Clozapine, olanzapine, risperidone, haloperidol, prazosin, propranolol, and ritanserin were each dissolved in distilled water with 2–3 drops of lactic acid and pH-adjusted to 6.0–7.0 with NaOH. For mouse drug discrimination studies, CNO was also dissolved in this vehicle. For rat drug discrimination studies and for mouse and rat pharmacokinetic analyses, CNO was dissolved in bacteriostatic saline containing v/v 2.5–5.0% dimethyl sulfoxide (Sigma-Aldrich) and 10% Cremophor EL (Sigma-Aldrich).
For mouse drug discrimination studies, all drugs were administered s.c. at a volume of 10 ml/kg, 30 min prior to session onset. For rat drug discrimination studies, all drugs were administered i.p. at a volume of 1 ml/kg. Clozapine was administered 60 min prior to session onset, while olanzapine, risperidone, prazosin, and propranolol were administered 30 min prior to session onset. CNO was tested at both 30 and 60 min pretreatment times. All drug doses are expressed as the salt weight.
Manvich D.F., Webster K.A., Foster S.L., Farrell M.S., Ritchie J.C., Porter J.H, & Weinshenker D. (2018). The DREADD agonist clozapine N-oxide (CNO) is reverse-metabolized to clozapine and produces clozapine-like interoceptive stimulus effects in rats and mice. Scientific Reports, 8, 3840.
Full text: Click here
Publication 2018
Anabolism Clozapine cremophor EL Discrimination, Psychology Haloperidol Lactic Acid Mice, House Olanzapine Pharmaceutical Preparations Prazosin Propranolol Risperidone Ritanserin Saline Solution Sodium Chloride Sulfoxide, Dimethyl
5
Augmenting SRI-Resistant OCD Treatment
Cited 11 times
Eligible patients were adults (aged 18–70 years) with a principal diagnosis of OCD (≥1 year), who were receiving an SRI at a stable dose (≥12 weeks), and who remained at least moderately symptomatic (Yale-Brown Obsessive Compulsive Scale11 (link),12 (link) [Y-BOCS] score ≥16). Consistent with the literature at the time this study was initiated,1 (link),9 (link) an optimal SRI dose was defined as the following: clomipramine hydrochloride, at least 225 mg/d; fluoxetine, at least 60 mg/d; paroxetine hydrochloride, at least 60 mg/d; sertraline hydrochloride, at least 200 mg/d; fluvoxamine, at least 250 mg/d; citalopram hydrobromide, at least 60 mg/d; and escitalopram oxalate, at least 30 mg/d. However, patients unable to tolerate doses this high because of adverse effects were also eligible if at their maximally tolerated dose. At least 12 weeks at this dose was required so that patients had likely experienced maximal SRI benefit.1 (link) Except for antipsychotics, concomitant psychotropics were permitted if the dose was stable (≥4 weeks), remained stable during the study, and was not contraindicated with risperidone.
Patients were excluded for bipolar and psychotic disorders, substance abuse or dependence in the past 3 months, prominent suicidal ideation, a17-item Hamilton Depression Scale(HAM-D)13 (link) score indicating severe depression (>25), or hoarding as the only OCD symptom. Other Axis I diagnoses were permitted if OCD was the most severe and impairing. Patients were excluded if they had an unstable medical or neurological condition that increased the risk of participation (eg, dementia), were pregnant or nursing, or had previously received risperidone (≥0.5 mg/d for 8 weeks) or EX/RP (≥8 sessions within 2 months) while receiving an SRI as described earlier. Patients were also excluded if receiving their first SRI with no response because practice guidelines1 (link) suggest switching to another SRI first.
Eligibility was determined by trained clinicians with expertise in OCD and related disorders. Psychiatric diagnoses were confirmed by trained raters prior to study entry using the Structured Clinical Interview for DSM-IV Axis I Disorders–Patient Edition.14 Treatment history was confirmed with the referring clinician and/or medical record review.
Simpson H.B., Foa E.B., Liebowitz M.R., Huppert J.D., Cahill S., Maher M.J., McLean C.P., Bender J J.r., Marcus S.M., Williams M.T., Weaver J., Vermes D., Van Meter P.E., Rodriguez C.I., Powers M., Pinto A., Imms P., Hahn C.G, & Campeas R. (2013). Cognitive-Behavioral Therapy vs Risperidone for Augmenting Serotonin Reuptake Inhibitors in Obsessive-Compulsive Disorder: A Randomized Clinical Trial. JAMA psychiatry, 70(11), 1190-1199.
Publication 2013
Adult Antipsychotic Agents Citalopram Hydrobromide Dementia Diagnosis Diagnosis, Psychiatric Eligibility Determination Epistropheus Escitalopram Oxalate Fluoxetine Fluvoxamine Hydrochloride, Clomipramine Nervous System Disorder Paroxetine Hydrochloride Patients Psychotic Disorders Psychotropic Drugs Risperidone Sertraline Hydrochloride Substance Abuse

Most recents protocols related to «Risperidone»

1
Pharmacological Modulation of Behavioral Tests
Risperidone (0.05 mg/kg/d, R3030, Sigma-Aldrich) was administered 1 h before the behavioral test. MK-801 [(+)-MK-801 hydrogen maleate, M107, Sigma-Aldrich, 0.2 mg/kg] was administered by i.p. injection once daily starting 2 wk before behavioral tests. Amthamine (ab120778, Abcam, 1 mM, 500 nL), betazole (HY-B1557, MedChemExpress, 10 mM, 500 nL), or ZD7288 (ab120102, Abcam, 1 mM, 500 nL) was administrated into two sides of the mPFC via cannulas 30 min before the test.
Ma Q., Jiang L., Chen H., An D., Ping Y., Wang Y., Dai H., Zhang X., Wang Y., Chen Z, & Hu W. (2023). Histamine H2 receptor deficit in glutamatergic neurons contributes to the pathogenesis of schizophrenia. Proceedings of the National Academy of Sciences of the United States of America, 120(9), e2207003120.
Publication 2023
amthamine Behavior Test Betazole Cannula hydrogen maleate MK-801 Risperidone ZD 7288
2
Restless Legs Syndrome and Dementia Risk
Chi-square for categorical variables and Mann–Whitney U test for continuous variables due to non-normality were used to compare the baseline characteristics between patients with RLS and RLS-free controls. Cox proportional hazards regression models were applied to explore the association between RLS and the risk of dementia after adjusting for age, sex, income, residence, CCI, and history of other comorbidities. Among the Cox regression models, we used the Fine–Gray subdistribution hazard model with mortality as a competing risk given the old age of the study population. The proportional hazard assumption was satisfied in our Cox model (Schoenfeld individual test p-value > 0.05).
Sensitivity analyses were performed using four different models. In model 1, dementia was defined as the prescription of anti-dementia medications (donepezil, rivastigmine, galantamine, and memantine) at least twice and a diagnosis of the ICD-code of dementia. Although these medications were approved for only AD (rivastigmine additionally for Parkinson’s disease dementia), they can be used for cognitive symptoms in other types of dementia based on recommendations from multiple guidelines [31 (link)–33 (link)]. The previous study revealed that the definition of all-cause dementia by ICD-10 code plus anti-dementia medications had a positive predictive value of 94.7% when reviewing the medical records of 972 patients in two hospitals [34 (link)]. In model 2, medication history was added to the ICD code to define RLS. Patients with RLS ICD-code (G25.8) who had taken dopamine agonists (ropinirole or pramipexole) twice or more were regarded as patients with RLS (n = 1458). In this sensitivity model, we excluded patients with Parkinson’s disease because they could also take dopamine agonists. In model 3, patients taking antipsychotic agents were excluded because the antidopaminergic property of antipsychotic agents could lead to a misdiagnosis of RLS (n = 2482). The following antipsychotic agents approved in South Korea were used in this study: haloperidol, sulpiride, chlorpromazine, perphenazine, pimozide, risperidone, olanzapine, quetiapine, paliperidone, amisulpride, aripiprazole, ziprasidone, clozapine, blonanserin, and zotepine. In model 4, patients with RLS only diagnosed by psychiatrists or neurologists were included (n = 1154) to preclude the possible misdiagnosis by non-expert physicians.
To evaluate the effect of dopamine agonists (pramipexole and ropinirole) on the development of dementia, the risk of dementia was compared after dividing RLS patients by dopamine agonist use. Patients with RLS who were prescribed pramipexole or ropinirole at least once were considered dopamine agonist users. All missing data were addressed using listwise deletion. Data processing and statistical analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC, USA). Statistical significance was set at a two-tailed p-value of < 0.05.
Kim K.Y., Kim E.H., Lee M., Ha J., Jung I, & Kim E. (2023). Restless leg syndrome and risk of all-cause dementia: a nationwide retrospective cohort study. Alzheimer's Research & Therapy, 15, 46.
Full text: Click here
Publication 2023
Age Groups agonists Amisulpride Antipsychotic Agents Aripiprazole blonanserin Chlorpromazine Clozapine Deletion Mutation Donepezil Dopamine Agonists Dopamine Effect Galantamine Haloperidol Hypersensitivity Memantine Neurobehavioral Manifestations Neurologists Olanzapine Paliperidone Parkinson Disease Patients Perphenazine Pharmaceutical Preparations Physicians Pimozide Pramipexole Prescription Drugs Presenile Dementia Psychiatrist Quetiapine Risperidone Rivastigmine ropinirole Sulpiride ziprasidone zotepine
3
Observational and Interventional Studies on Mood Disorders
We retrieved all observational studies and clinical trials related to patients with mood disorders or to their caregivers. In the case of clinical trials, we included all interventions, such as drugs, lifestyle modification, psycho-educational treatments, and behavioral treatments. We extracted data for studies registered in the CTRI database between June 15, 2009 and December 31, 2019. We used the three advanced search options at the CTRI website: ‘scientific title of the study,’ ‘health condition/problem studied,’ and ‘intervention and comparator agent’ to identify relevant observational studies and interventional clinical trials.
For the first two options, we searched the database using disorder keywords such as “depression”, “depressive disorder”, “major depressive disorder”, “treatment-resistant depression”, “mania”, “bipolar disorder”, and “bipolar depression”, entered individually. For the third option, we searched using names of psychotropic drugs and other treatments, such as “olanzapine”, “risperidone”, “cognitive behaviour therapy”, “electroconvulsive therapy”, repetitive transcranial magnetic stimulation, and deep brain stimulation, again entered individually. Two authors (NV, RJ) independently searched the CTRI database using these strategies, after which a final list of studies satisfying the eligibility criteria was made by removing duplicates. We excluded studies involving interventions related to Ayurveda, Unani, and other alternative systems of medicine because the results of such studies tend to be published in journals and other destinations that might not have been accessible to us in our literature search. We also excluded studies that were not conducted primarily in patients with the disorders listed above.
Menon V., Varadharajan N., Joseph R., Praharaj S.K, & Andrade C. (2023). Publication of studies registered in Clinical Trials Registry of India: An audit of mood disorder research protocols from 2009-2019. Indian Journal of Psychiatry, 65(1), 68-74.
Publication 2023
Behavior Therapy Bipolar Disorder Cognitive Therapy Deep Brain Stimulation Depression, Bipolar Depressive Disorder, Treatment-Resistant Disorder, Depressive Electroconvulsive Therapy Eligibility Determination Major Depressive Disorder Mania Mood Disorders Olanzapine Patients Pharmaceutical Preparations Psychotropic Drugs Risperidone Transcranial Magnetic Stimulation, Repetitive
4
Assessing Treatment-Resistant Depression with ECT
Patients were classified as having TRD if at least two subsequent pharmacological treatment trials for depression (a different Anatomic Therapeutic Chemical classification code, or an antidepressant add-on medication) were recorded in the PDR during the 2 years before ECT. To be considered adequate, a treatment trial needed to be at least 28 days long, reflecting a duration commonly required for antidepressants to have effect. The duration of each filled prescription was estimated from package size, dosage and prescription text. Add-on medications were defined as lithium, risperidone, olanzapine, aripiprazole and quetiapine, which are recommended for the treatment of TRD by guidelines.5 Patients not meeting criteria for TRD were classified as ‘non-TRD’. A validation study21 (link) has shown that patients identified as TRD with this register-based method have similar characteristics as adaptations of clinical methods. In patients with depression, incidence rates of TRD as identified by register-based methods are similar in Swedish2 (link) and Danish22 studies.
Additionally, we categorised exposure according to the number of pharmacological treatment trials before ECT, ranging from zero to five or more.
Nygren A., Reutfors J., Brandt L., Bodén R., Nordenskjöld A, & Tiger M. (2023). Response to electroconvulsive therapy in treatment-resistant depression: nationwide observational follow-up study. BJPsych Open, 9(2), e35.
Full text: Click here
Publication 2023
Acclimatization Antidepressive Agents Aripiprazole Lithium Olanzapine Patients Pharmaceutical Preparations Pharmacotherapy Quetiapine Risperidone
5
COVID-19 Patients' Psychiatric Drug Intervention
The National Exhibition and Convention Centre of Shanghai Fangcang Shelter Hospital were constructed as a temporary medical building for the admission and hospitalisation of infected patients with moderate and mild COVID-19 symptoms. It received 174,308 infected patients from 9 April 2022 to 31 May 2022. The infected patients were cured to discharge or transferred to a designated hospital for treatment with severe symptoms. The information of infected patients who used the drugs as listed (risperidone, olanzapine, quetiapine, paroxetine, sertraline, venlafaxine, flupentixol-melitracen, escitalopram oxalate, zolpidem tartrate, estazolam) was collected as the drug intervention group. Patients diagnosed of schizophrenia were mainly prescribed with risperidone, olanzapine and quetiapine. For depression diagnosis, patients were prescribed with paroxetine, sertraline, venlafaxine, flupentixol-melitracen or escitalopram oxalate according their individual specific symptom. Patients with insomnia were prescribed with zolpidem. And patients with symptoms of anxiety or sleep disorders were intervened with estazolam. The information was integrated when the infected individual used different drugs were classified listed as schizophrenia, depression, insomnia, anxiety or sleep disorder according to the symptom severity from severe to mild. A total of 6,218 individuals treated with the list drugs in the Fangcang shelter hospital were processed. Simultaneously, information of a corresponding comparable control group of 30,000 infected patients who has no listed psychiatric drug intervention was randomly drawn out based on the number of patients in the drug intervention group.
Yu P., Bian X., Xie Z., Wang X., Zhang X., Gu Z., Yang Z., Jing F., Qiu W., Lin J., Tang J., Huang C., Zhang Y., Chen Y., Zhang Z., Bi Y., Shang H, & Chen E. (2023). Risk factor analysis of omicron patients with mental health problems in the Fangcang shelter hospital based on psychiatric drug intervention during the COVID-19 pandemic in Shanghai, China. Frontiers in Psychiatry, 14, 1100849.
Full text: Click here
Publication 2023
A 218 Anxiety Conferences COVID 19 Diagnosis Escitalopram Oxalate Estazolam flupentixol, melitracen drug combination Olanzapine Paroxetine Patient Discharge Patients Pharmaceutical Preparations Quetiapine Risperidone Schizophrenia Sertraline Sleep Disorders Sleeplessness Venlafaxine Zolpidem Zolpidem Tartrate

Top products related to «Risperidone»

1
Risperidone by Merck Group
Sourced in United States, United Kingdom, France, Germany
Risperidone is a medication used to treat various psychiatric conditions, including schizophrenia, bipolar disorder, and certain symptoms of autism. It is an antipsychotic drug that works by affecting the balance of certain natural substances in the brain.
2
Haloperidol by Merck Group
Sourced in United States, United Kingdom, Sao Tome and Principe, Germany, France, Japan, Spain
Haloperidol is a laboratory reagent used in various research and analytical applications. It is a butyrophenone-class antipsychotic drug that acts as a dopamine D2 receptor antagonist. Haloperidol is commonly used as a reference standard and in the development and validation of analytical methods.
3
Clozapine by Merck Group
Sourced in United States, United Kingdom, Germany, Sao Tome and Principe, Israel, Macao
Clozapine is a laboratory instrument used for the detection and quantification of the antipsychotic drug clozapine. It is designed to provide accurate and reliable measurements of clozapine concentrations in biological samples, such as blood or plasma.
4
Aripiprazole by Merck Group
Sourced in United States
Aripiprazole is a laboratory reagent manufactured by Merck Group. It is a synthetic compound used in various research applications, including pharmaceutical development and biological studies. Aripiprazole functions as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors.
5
Olanzapine by Merck Group
Sourced in United States, United Kingdom
Olanzapine is a pharmaceutical compound used as a laboratory standard in research and development. It is a white crystalline powder that is soluble in organic solvents. Olanzapine is commonly used as a reference substance in analytical and bioanalytical methods for the identification and quantification of related substances.
6
Clozapine by Bio-Techne
Sourced in United Kingdom
Clozapine is a laboratory product manufactured by Bio-Techne. It is a tricyclic dibenzodiazepine compound used for research purposes.
7
Risperidone by Johnson & Johnson
Sourced in China
Risperidone is a pharmaceutical product manufactured by Johnson & Johnson. It is a medication used to treat certain mental health conditions. The core function of Risperidone is to act as an antipsychotic drug.
8
Risperidone by Bio-Techne
Sourced in United Kingdom
Risperidone is a laboratory reagent used for research purposes. It is a synthetic compound that acts as an antipsychotic medication. Risperidone has a core function of modulating the activity of certain neurotransmitter receptors in the brain.
9
Dimethyl sulfoxide (dmso) by Merck Group
Sourced in United States, Germany, United Kingdom, China, Italy, Sao Tome and Principe, France, Macao, India, Canada, Switzerland, Japan, Australia, Spain, Poland, Belgium, Brazil, Czechia, Portugal, Austria, Denmark, Israel, Sweden, Ireland, Hungary, Mexico, Netherlands, Singapore, Indonesia, Slovakia, Cameroon, Norway, Thailand, Chile, Finland, Malaysia, Latvia, New Zealand, Hong Kong, Pakistan, Uruguay, Bangladesh
DMSO is a versatile organic solvent commonly used in laboratory settings. It has a high boiling point, low viscosity, and the ability to dissolve a wide range of polar and non-polar compounds. DMSO's core function is as a solvent, allowing for the effective dissolution and handling of various chemical substances during research and experimentation.
10
Risperidone by LGC
Sourced in Canada
Risperidone is a laboratory equipment product used for the analysis and quantification of the antipsychotic drug risperidone. It provides accurate and reliable measurements of risperidone concentrations in various samples, supporting research and clinical applications.

More about "Risperidone"

Risperidone is an atypical antipsychotic medication commonly used to treat schizophrenia, bipolar disorder, and other mental health conditions.
It works by blocking certain receptors in the brain, helping to reduce symptoms like hallucinations, delusions, and mood swings.
Risperidone is generally well-tolerated, but may cause side effects such as weight gain, drowsiness, and extrapyramidal symptoms.
Researchers studying Risperidone can utilize PubCompare.ai, a powerful tool that helps optimize research protocols, identify the best products, and enhance reproducibility and accuracy.
PubCompare.ai allows researchers to locate protocols from literature, pre-prints, and patents, and leverage AI-driven comparisons to find the most suitable protocols and products for their studies.
Risperidone is often compared to other atypical antipsychotics like Haloperidol, Clozapine, Aripiprazole, and Olanzapine.
These medications work in similar ways to Risperidone, but may have different side effect profiles and dosing requirements.
DMSO (dimethyl sulfoxide) is sometimes used as a solvent for Risperidone and other antipsychotic drugs in research settings.
By incorporating synonyms, related terms, abbreviations, and key subtopics, researchers can optimize their Risperidone studies and enhance the overall quality and impact of their work.
PubCompare.ai is a valuable tool that can help streamline the research process and improve reproducibility, leading to more accurate and reliable findings.